Growth and scale EPICENTRE Biotechnologies operates within a biotechnology space with a revenue range of 1M-10M and a modest employee base (51-200), presenting a target for expansion opportunities through higher-margin kits, custom reagents, or expanded service offerings to academic, commercial, and government labs.

Strategic acquisition As a wholly owned subsidiary of Illumina since 2011, EPICENTRE is positioned to leverage Illumina’s extensive genomics ecosystem for co-developed products, bundled solutions, or cross-sell opportunities to Illumina customers.

Genomics focus The company’s portfolio centers on DNA/RNA sequencing, gene expression, PCR/RT-PCR, and microbial genomics, indicating strong potential for sales of complementary kits, reagents, and automation-friendly workflows to accelerate genomics and transcriptomics research.

Global reach With products used worldwide in academic, commercial, and government labs, there are opportunities to tailor regional support, language-specific materials, and localized logistics to improve adoption, training, and repeat purchases.

Collaborative opportunities Recent partnerships and media engagements suggest a receptiveness to collaboration and co-marketing; pursue opportunities around joint events, case studies, and educational programs that showcase integrated workflow solutions for genomics research.